Update on the use of rituximab for intractable rheumatoid arthritis
R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an ina...
Enregistré dans:
Auteur principal: | |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/967a4a12fae44754a99f5bcadd572bbe |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|